08-Jan-2008 - Illumina, Inc.

Illumina Announces Corporate Reorganization

Illumina, Inc. announced that it has reorganized its operating structure to further leverage the synergies between its sequencing and genotyping businesses. Under the new structure, a newly created Life Sciences Business Unit will include all products and services related to the research market namely the BeadArray, BeadXpress and Sequencing product lines. The Company has also created a Diagnostics Business Unit to put more focus on the emerging opportunity in molecular diagnostics. The Diagnostics Business Unit will develop diagnostic content for the BeadXpress system, and ultimately for Illumina's Sequencing products.

"Over the last few years we have experienced incredible growth. This new organizational structure provides the foundation to continue scaling our global operations and more effectively leverage our technology assets to capitalize on future opportunities. A specific result will be the acceleration of the integration of our sequencing and genotyping technologies. Additionally, it will enable us to put more focus on developing our diagnostics business," said Jay Flatley, President and Chief Executive Officer of Illumina.

The timing of this reorganization was driven by several management changes. John Stuelpnagel, Senior Vice President, Chief Operating Officer and General Manager, Arrays has decided to move to part-time status as of April 1, 2008. Dr. Stuelpnagel is expected to have a continuing role with the company working on key projects as an Illumina Fellow. Additionally, he will step down from Illumina's Board of Directors as of that date.

John West, Senior Vice President and General Manager, Sequencing has announced his resignation effective February 1, 2008.

Effective immediately, Christian Henry, Senior Vice President and Chief Financial Officer will take on the role of Acting General Manager of the Sequencing business. In addition to his other duties, Mr. Henry's primary goal will be to effectively manage the integration of the Sequencing business into the new combined Life Sciences Business Unit. The integration is expected to be completed before the end of the second quarter.

Facts, background information, dossiers
  • Life Sciences
  • genotyping
  • diagnostics
  • services
  • molecular diagnostics
More about Illumina